In this article, we will discuss: 11 Best GLP-1 and Weight Loss Stocks to Invest in.

GLP-1 medicines are a type of prescription that mimics a natural hormone that regulates blood sugar and appetite. Weight loss stocks are shares in firms that develop, manufacture, or sell GLP-1 pharmaceuticals and other weight-loss treatments, and they represent a potentially profitable investment opportunity due to the expanding market for these drugs.

Eli Lilly’s Mounjaro (tirzepatide) decreased major adverse cardiovascular events by 8% more than Trulicity (dulaglutide) and dropped all-cause mortality by 16% in a nearly five-year trial involving almost 13,000 patients with type 2 diabetes and high cardiovascular risk. Both drugs had comparable safety profiles. However, 13.3% of Mounjaro patients had to stop taking it due to gastrointestinal side effects, compared to 10.2% of Trulicity patients. Furthermore, Mounjaro showed better weight and blood sugar reductions.

Kenneth Custer, the president of Lilly’s cardiometabolic health division, stated that the latest findings “make Mounjaro an even stronger choice for patients.” Non-inferiority in heart protection was the primary outcome of the trial. Trulicity, authorized in 2014, reduced cardiac risk by 12% and was Lilly’s best seller in 2022, with sales of $7.4 billion. Mounjaro overtook it in 2023, with a total of $11.5 billion. Eli Lilly intends to provide the results to the FDA later this year in anticipation of a 2026 expanded approval.

With that said, here are the  11 Best GLP-1 and Weight Loss Stocks to Invest in.

Our Methodology

We sifted through the ETFs’ online rankings to form an initial list of the 20 Best GLP-1 and Weight Loss Stocks. From the resultant dataset, we chose 11 stocks with the highest number of hedge fund investors, using Insider Monkey’s database of 1000 hedge funds in Q1 2025 to gauge hedge fund sentiment for stocks. We have used the stock’s market cap as of August 4, 2025, as a tie-breaker in case two or more stocks have the same number of hedge funds invested.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

11. Structure Therapeutics Inc. (NASDAQ:GPCR)

Number of Hedge Fund Holders: 41

Market cap as of August 4: $965.47 million

Structure Therapeutics Inc. (NASDAQ:GPCR) showcased preclinical findings for ACCG-2671 and GSBR-5595 in two late-breaking posters at the ADA 85th Scientific Sessions. ACCG-2671, an oral dual amylin and calcitonin receptor agonist, led to considerable, dose-dependent weight loss in obese rats and improved outcomes when coupled with semaglutide. Clinical studies are anticipated to begin before the end of 2025. A GLP-1 receptor agonist called GSBR-5595 has shown neuroprotective effects in animal models of Parkinson’s disease by enhancing motor function and raising the number of dopaminergic neurons.

CEO Raymond Stevens pointed out ACCG-2671’s potential as a distinct oral medication for obesity, citing expanding evidence of amylin receptor targeting. Poster #2184-LB described ACCG-2671’s high binding affinity for human CTR and AMY3R receptors, as well as its synergistic effect with semaglutide in encouraging superior weight reduction. The benefit of GSBR-5595 in Parkinson’s models was noted in Poster #1985-LB, showing that GLP-1 receptor agonists might have many uses. These findings support Structure Therapeutics Inc. (NASDAQ:GPCR)’s plan to provide injectable therapy substitutes with scalable oral small molecules. It is one of the Best Weight Loss Stocks.

10. Viking Therapeutics, Inc. (NASDAQ:VKTX)

Number of Hedge Fund Holders: 41

Market cap as of August 4: $3.82 billion

Viking Therapeutics, Inc. (NASDAQ:VKTX) and CordenPharma have concluded a multi-year manufacturing contract to facilitate the commercial production of VK2735, the company’s dual GLP-1/GIP agonist for obesity. The deal guarantees a yearly supply of more than 1 billion oral pills, 100 million autoinjectors, 100 million vial/syringe units, and several metric tons of API. Prepayments of $150 million will be made by the firm through 2028 and applied to upcoming orders. The agreement offers specific capacity for both oral and subcutaneous formulations.

Viking Therapeutics, Inc. (NASDAQ:VKTX)’s main metabolic therapy candidate, VK2735, is being developed as an injectable and oral medication. Phase 3 development for the injectable version is scheduled to start in Q2 2025, while the company is now completing a Phase 2 VENTURE-Oral trial. The business still owns global rights to VK2735. CEO Brian Lian noted that CordenPharma’s end-to-end supply capability and peptide production experience are essential for growing commercial demand. Viking Therapeutics, Inc. (NASDAQ:VKTX) anticipates that the product will have conventional pharmaceutical margins and have a multibillion-dollar potential. It is among the Best Weight Loss Stocks.

9. Scholar Rock Holding Corporation (NASDAQ:SRRK)

Number of Hedge Fund Holders: 48

Scholar Rock Holding Corporation (NASDAQ:SRRK) reported positive topline results from its Phase 2 EMBRAZE trial, which found that apitegromab effectively retained lean mass in individuals experiencing tirzepatide-induced weight loss. Patients treated with apitegromab and tirzepatide over 24 weeks retained 4.2 pounds of lean mass (54.9%) more than those treated with tirzepatide alone (p=0.001). Apitegromab improved the quality of weight loss, which led to 85% fat loss compared to 70% fat in the control group, while both groups experienced similar fat loss (18.8 lbs vs. 17.7 lbs). Apietegromab was well tolerated and did not cause any significant side effects.

The EMBRAZE trial enrolled 87 overweight or obese people and randomly assigned them to receive tirzepatide with apitegromab or a placebo for 24 weeks. Scholar Rock Holding Corporation (NASDAQ:SRRK)’s Rock anti-myostatin antibody platform attempts to stop lean mass loss in order to lower health hazards related to GLP-1 medications. According to Dr. Akshay Vaishnaw, President of R&D, this encourages further advancement in neuromuscular disorders. Later in 2025, Scholar Rock Holding Corporation (NASDAQ:SRRK) intends to submit an IND for its subcutaneous SRK-439. It is ranked ninth on our list of the Best Weight Loss Stocks.